drugset / Trial / NCT04470778

Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

NCT04470778

Phase 1 Completed 35 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to investigate the effect of gastric pH changes due to famotidine administration on the drug levels of prototype BMS-986256 tablet formulation in healthy participants.

Timeline

Start
2020-07-20
Primary completion
2021-03-21
Completion
2021-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Afimetoran Small molecule
Subject Famotidine Other / unclassified

Indications

No indication recorded.